Stock listing

NASDAQ:LTRN Lantern Pharma Inc. Stock

Home listing (NASDAQ) of Lantern Pharma Inc.

Follow Lantern Pharma Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:LTRN

$0.668 USD +0.002 (+0.2%)

Close on Oct 16, 2026

Since Jul 6, 2026 -83.0% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$0.625 – $0.735 USDOct 16, 2026
Volume
257,810 sharesOct 16, 2026
Market value
$9.99M USDAt the close on Oct 16, 2026 · price × 14.94M shares outstanding
Lantern Pharma Inc. logo
Ticker
NASDAQ:LTRN
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Calls

Replays

  • Lantern Pharma (NASDAQ:LTRN) Q2 2026 Earnings Call

    Fri, Aug 14, 2026 · 9:00 AM ET

    Watch Transcript

  • Lantern Pharma (NASDAQ:LTRN) Q4 2025 Earnings Call

    Mon, Mar 30, 2026 · 4:30 PM ET

    Watch Transcript

  • Lantern Pharma (NASDAQ:LTRN) Q3 2025 Earnings Call

    Thu, Nov 13, 2025 · 9:00 AM ET

    Watch Transcript

Latest news

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026

Oct 8, 2026

Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

Oct 7, 2026

Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering

Sep 30, 2026

Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering

Sep 29, 2026

Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12: 30 PM ET

Sep 23, 2026

Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas

Sep 22, 2026

Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23

Sep 17, 2026

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 14, 2026

Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9: 00 a.m. ET

Aug 7, 2026

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

Aug 3, 2026

All Lantern Pharma Inc. news

Financings

  • Registered direct offering of common stock (or pre-funded warrants) with concurrent unregistered warrants

    Sep 30, 2026

    Closed: US$4M raised · US$1.09 a share · Warrants at US$1.09 for 60 months · Rodman & Renshaw LLC

    Dealers: Rodman & Renshaw LLC (lead)

    Use of proceeds: Working capital and other general corporate purposes

    Announced Sep 29, 2026 · Closed Sep 30, 2026

Read by 6ix AI from the company's releases

Decks

Lantern Pharma Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
39 in the last 12 months · 185 in all · newest Oct 8, 2026 · oldest 2020
Calls
16 calls with a replay · 16 with a transcript · latest Aug 14, 2026
Decks
33 decks · latest Sep 23, 2026

Where Lantern Pharma Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:LTRN · Home listing · This pageNASDAQUnited StatesUSD
BOATS:LTRNBOATSUnited StatesUSD

Log in to ask 6ix AI your own questions about Lantern Pharma Inc.